Actuate Therapeutics, Inc.
Sarah Majka has a diverse work experience spanning multiple roles and industries. Sarah recently joined Actuate Therapeutics, Inc. in March 2023 as an Associate Manager of Clinical Operations. Prior to this, Sarah worked at Syneos Health from March 2022 to February 2023, where they served as a Senior Project Specialist. Sarah also gained experience as a Clinical Trial Assistant I at Monopar Therapeutics Inc. from December 2020 to February 2022. Furthermore, Sarah worked as an Exam Proctor at the University of Illinois at Urbana-Champaign from January 2020 to April 2020, and as a Field Inspector at Clarke from June 2019 to August 2019.
Sarah Majka attended the University of Illinois Urbana-Champaign from 2016 to 2020, where they pursued a degree in Integrative Biology. Sarah obtained the CNPR Exam certification from the National Association of Pharmaceutical Sales Reps in July 2020.
This person is not in any teams
This person is not in any offices
Actuate Therapeutics, Inc.
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, andcommercialize new agents that target GSK-3β.Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.